Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML

Bone Marrow Transplantation

Volumn 45, Issue 12, 2010, Pages 1692-1698

  Locke, F L ^a   Artz, A ^a   Rich, E ^a   Zhang, Y ^a   Van Besien, K ^a   Stock, W ^a  

^a University of Chicago   (United States)

Author keywords

allogeneic; AML; clofarabine; refractory; relapsed

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CLOFARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW BIOPSY; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATITIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MORTALITY; MUCOSA INFLAMMATION; PRIORITY JOURNAL; SIDE EFFECT;

ADENINE NUCLEOTIDES; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650205593     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.32     Document Type: Article

References (22)

1. Craddock C, Tauro S, Moss P, Grimwade D. Biology and management of relapsed acute myeloid leukaemia. Br J Haematol 2005; 129: 18-34.
2. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003; 102: 3052-3059.
3. Michallet M, Thomas X, Vernant JP, Kuentz M, Socie G, Esperou-Bourdeau H et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for adVanced stage acute myeloblastic leukemia: A retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 2000; 26: 1157-1163.
4. Horowitz MM, Rowlings PA. An update from the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry on current activity in hematopoietic stem cell transplantation. Curr Opin Hematol 1997; 4: 395-400.
5. Van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk adVanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5728-5738.
6. Kebriaei P, Kline J, Stock W, Kasza K, Le Beau MM, Larson RA et al. Impact of disease burDen at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant 2005; 35: 965-970.
7. Oliansky DM, Appelbaum F, Cassileth PA, Keating A, Kerr J, Nieto Y et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: An eviDence-based review. Biol Blood Marrow Transplant 2008; 14: 137-180.
8. Yakoub-Agha I, de La Salmoniere P, Ribaud P, Sutton L, Wattel E, Kuentz M et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 2000; 18: 963-971.
9. Scott BL, Storer B, Loken MR, Storb R, Appelbaum FR, Deeg HJ. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with adVanced myelodysplastic syndrome. Biol Blood Marrow Transplant 2005; 11: 65-73.
10. Platzbecker U, Thiede C, Fussel M, Geissler G, Illmer T, Mohr B et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia 2006; 20: 707-714.
11. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092-1099.
12. Van Besien K, Kline J, Godley LA, Larson RA, Nguyen VH, ODenike O et al. Phase I-II Study of clofarabine-melphalanalemtuzumab (CMA) conditioning for allogeneic hematopoietic cell transplantation (HCT) in patients with adVanced hematologic malignancies: Determination of MTD and outcomes. ASH 51st Annual Meeting 2009: Abstr 197.
13. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A et al. Early blast clearance by remission induction therapy is a major indepenDent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: Data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003; 101: 64-70.
14. O'Donnell PH, Artz AS, Undevia SD, Hart J, Van Besien K. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoetic stem cell transplantation (alloHCT). J Clin Oncol 2008; 26(Suppl): Abstr 7042.
15. Sobecks RM, Daugherty CK, Hallahan DE, Laport GF, Wagner ND, Larson RA. A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of adVanced hematologic malignancies. Bone Marrow Transplant 2000; 25: 807-813.
16. Rich ES, Artz A, Karrison T, Wickrema A, Joseph L, Godley L et al. Preliminary results of combined haploiDentical-cord blood transplantation for patients lacking HLA iDentical donors. ASH 50th Annual Meeting 2008: Abstr 3015.
17. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reducedintensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387-9393.
18. Sierra J, Storer B, Hansen JA, Martin PJ, Petersdorf EW, Woolfrey A et al. Unrelated donor marrow transplantation for acute myeloid leukemia: An update of the Seattle experience. Bone Marrow Transplant 2000; 26: 397-404. (Pubitemid 30649555)
19. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, RaVandi F et al. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 2008; 113: 2090-2096.
20. Erba HP, Kantarjian H, Claxton DF, Arellano M, Lyons RM, Kovacsovics TJ et al. Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy. Blood 2008; 112: Abstr 558.
21. Faderl S, RaVandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112: 1638-1645.
22. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 2007; 13: 454-462. (Pubitemid 46421890)